SELLAS Life Sciences announced positive preclinical data for its drug SLS009, demonstrating synergistic activity and increased apoptosis in MYC-amplified pancreatic cancer models, including those resistant to a recently approved RAS inhibitor. This data suggests SLS009 could enhance existing RAS-directed therapies and offers a potential new strategy for treating aggressive pancreatic cancers.
SELLAS Life Sciences announced positive preclinical data for its highly selective CDK9 inhibitor, SLS009, in pancreatic cancer models. The data showed SLS009 increased apoptosis significantly, even in models resistant to a recently approved RAS inhibitor (daraxonrasib), and demonstrated synergistic activity when combined with daraxonrasib and a BET inhibitor. This is significant because MYC amplification is a known mechanism of resistance to RAS-targeting therapies, and SLS009's ability to overcome this resistance presents a potential breakthrough. For traders, this news offers a short-term positive catalyst for SLS, as it validates the drug's potential and expands its addressable market. Long-term implications depend on successful progression through clinical trials, but this preclinical data provides a strong foundation for future development and potential partnerships.